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Abstract
Background: Extracellular adenosine triphosphate (ATP) is up-regulated in the airways of patients with chronic
obstructive pulmonary disease (COPD), resulting in increased inflammation, bronchoconstriction, and cough. Although
extracellular ATP levels are tightly controlled by nucleoside triphosphate diphosphohydrolase-1 (NTPDase1; also known
as CD39) in the lungs, the role of CD39 in the pathology of COPD is unknown. We hypothesized that alterations in the
expression and activity of CD39 could be part of the mechanisms for initiating and perpetuating the disease.
Methods: We analyzed CD39 gene and protein expression as well as ATPase enzyme activity in lung tissue samples of
patients with COPD (n = 17), non-obstructed smokers (NOS) (n = 16), and never smokers (NS) (n = 13). Morphometry
studies were performed to analyze pulmonary vascular remodeling.
Results: There was significantly decreased CD39 gene expression in the lungs of the COPD group (1.17 [0.85–1.81])
compared with the NOS group (1.88 [1.35–4.41]) and NS group (3.32 [1.23–5.39]) (p = 0.037). This attenuation correlated
with higher systemic inflammation and intimal thickening of muscular pulmonary arteries in the COPD group. Lung
CD39 protein levels were also lower in the COPD group (0.34 [0.22–0.92]) compared with the NOS group (0.67 [0.32–1.06])
and NS group (0.95 [0.4–1.1) (p = 0.133). Immunohistochemistry showed that CD39 was downregulated in lung
parenchyma, epithelial bronchial cells, and the endothelial cells of pulmonary muscular arteries in the COPD
group. ATPase activity in human pulmonary structures was reduced in the lungs of patients with COPD.
Conclusion: An attenuation of CD39 expression and activity is presented in lung tissue of stable COPD
patients, which could lead to pulmonary ATP accumulation, favoring the development of pulmonary
inflammation and emphysema. This may be a mechanism underlying the development of COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is charac-
terized by small airway inflammation that causes airway
obstruction, parenchymal destruction, and emphysema
[1]. Cigarette smoking is the major risk factor for COPD,
being responsible not only for local inflammation but also
for the systemic inflammation that contributes to other
comorbidities that affect disease severity and mortality [2].
Although most cases of COPD relate to smoking, not all
smokers develop COPD, suggesting that the mechanisms
initiating and perpetuating the disease are not fully under-
stood [3]. Currently, no therapy effectively alters disease
progression or improves survival due to the complexity of
the signaling pathways that maintain the chronic inflam-
mation and tissue destruction [4].
In recent years, numerous studies have generated data
supporting the hypothesis that extracellular adenosine 5-
triphosphate (ATP) is involved in the pathogenesis of
COPD [5]. Specifically, increased pulmonary ATP levels
have been found in mice with acute lung inflammation
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and emphysema following tobacco smoke exposure [6, 7].
Furthermore, red blood cells (RBC) represent an import-
ant physiologic compartment of ATP and the level of ATP
in RBC in COPD patients is also significantly elevated [8].
In addition, in patients with COPD it has been shown that
ATP accumulation stimulates the recruitment and activa-
tion of lung neutrophils and macrophages, which in turn
enhance the release of proinflammatory and tissue-
degrading mediators [9]. The release of ATP from neutro-
phils triggered by cigarette smoke activates the ATP
receptor P2X7 for further activation of inflammasome
pathways [10]. In animal models, it has been demon-
strated that neutralizing intrapulmonary ATP levels or
blocking airway specific ATP receptor subtypes can inhibit
smoke-induced lung inflammation and confer protection
from developing emphysema [7].
Extracellular ATP levels in mammalian tissues are tightly
controlled by ecto-nucleotidases [11]. Among them,
nucleoside triphosphate diphosphohydrolase-1 (NTPDase1;
also known as CD39) is the most expressed purinergic
ecto-enzyme in human alveolar and bronchial epithelia,
submucosal glands, and fibroblasts [12]. CD39 is also found
in the vascular endothelium, where it regulates homeostasis
and is essential to angiogenesis and vasculogenesis [13].
Moreover, it regulates ATP-mediated P2 receptor signaling
by hydrolyzing ATP/adenosine 5-diphosphate (ADP) to
adenosine 5-monophosphate (AMP), which is then further
metabolized by ecto-5′-nucleotidase/CD73 to adenosine
[14]. Besides its general ecto-enzymatic functions, CD39
might modulate the function of neutrophil, macrophage,
and dendritic cells by facilitating the hydrolisis of extracel-
lular ATP and the further activation of the purinergic
receptors [15, 16].
The role of CD39 in COPD has previously been investi-
gated in an animal model of emphysema induced by
tobacco exposure [17] and in inflammatory cells of COPD
patients [17, 18], but its expression in human lung tissue is
unknown. To better understand the mechanisms under-
lying COPD pathology we compared CD39 expression and
activity in the lungs of patients with COPD (COPD group),
non-obstructed smokers (NOS group), and never smokers
(NS group). Our aim was to determine the expression and
activity of CD39, the most efficient NTPDase for degrading




We conducted a prospective study of 56 subjects who
underwent lobectomy or pneumonectomy of a solitary
pulmonary nodule at the Bellvitge University Hospital.
Preoperative functional measurements were performed
in all patients. Ten of them were excluded due to poor
quality or insufficient sample. Therefore, 46 patients
were included and according to their smoking history
and the results of pulmonary function tests, subjects
were classified as follows: (1) a COPD group, comprising
17 stable patients with COPD diagnosed according to
the GOLD recommendations [1]; (2) an NOS group,
comprising 16 smokers without COPD; and (3) an NS
groups comprising 13 patients who had never smoked.
Surgical lung samples were examined morphologically
and histologically by immunolabeling experiments,
molecular techniques, and enzymatic assays. All patients
signed an informed consent form in accordance with the
principles outlined in the Declaration of Helsinki, and
the study was approved by the local ethics committee
(CEIC, ref. PR330/15).
Sample collection and processing
All lung tissue samples were obtained and processed imme-
diately after surgery. Lung samples were divided into four
and processed as follows: gene expression studies (frozen at
− 80 °C in RNA Later; Qiagen, Hilden, Germany), morpho-
logical and immunological studies (immediately fixed, kept
overnight in formalin, and embedded in paraffin), protein
studies and enzymatic determination (directly frozen at −
80 °C), and in situ ATPase activity determination (fixed-for-
malin-lung samples were embedded in OCT freezing
medium [Tissue Tek®; Sakura Finetek, Zoeterwoude, the
Netherlands] and snap-frozen in dry ice). When sufficient
lung samples could not be obtained for all studies, sample
availability was prioritized in the given order.
Quantitative real-time polymerase chain reaction analysis
of CD39
Quantitative real-time polymerase chain reaction (qRT-
PCR) was performed, as previously described [19]. The
relative expression of CD39 in lung tissue samples was
determined using NTPD1 TaqMan Gene Expression
Assays (catalog number Hs00969559_m1, Applied Bio-
systems) and RNA18S5 (Taqman Assay, Hs03928985_g1,
Applied Biosystems) as the endogenous control for
normalization. Data are expressed as a relative quantifi-
cation (fold change ratio) of mRNA.
Vascular morphometry
The histological and morphometric characteristics of pul-
monary muscular arteries were analyzed in sections stained
with hematoxylin and eosin, and orcein, using a computer-
ized image analyzer, as previously reported [19, 20]. The
areas occupied by the lumen, the intima, and the muscular
layer are expressed as percentages of the total area encom-
passed by the external elastic lamina.
Immunohistochemistry
Formalin-fixed, paraffin-embedded lungs were sectioned
at a thickness of 4 μm. Sections underwent dewaxing,
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rehydration, antigen retrieval, and quenching of endogen-
ous peroxidase activity. After three rinses in phosphate
buffered saline (PBS), tissue sections were pre-incubated
for 1 h at room temperature in 1% bovine serum albumin
(Sigma-Aldrich, Sant Louis, Missouri, MO, USA), 0.2%
gelatin (Merck, Darmstadt, Germany) and 0.1% triton
(Sigma-Aldrich). Slices were then incubated overnight at
4 °C with mouse monoclonal antibody to human CD39
(Ref: ab178572, Abcam, Cambridge, UK) at 1/100, as the
primary antibody. After three washes in PBS-triton,
samples were incubated with the suitable avidin-biotin
complex/peroxidase (Vectastain Elite ABC kit, Vector La-
boratories, Burlingame, CA, USA), following the manufac-
turer’s protocol. Secondary antibody alone was routinely
included to detect non-specific binding and placenta was
used as positive control tissue for each experiment (data
not shown). Nuclei were counterstained with haematoxy-
lin, and the results were observed and photographed
under a light Leica DMD 108 microscope (Leica Micro-
systems, Wetzlar, Germany). Evaluation and recording
was by two investigators blinded to study conditions.
Label intensity was scored as negative (−), weak (+), inter-
mediate (++), or strongly positive (+++).
Western blot
Frozen samples of lung tissue were homogenized and
lysed in a RIPA lysis buffer (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, 1 mM EDTA) containing a protease
inhibitor cocktail (Roche Molecular Systems, Pleasanton,
CA). Protein from each sample (5 μg) was added to a 2×
Laemmli sample buffer (Bio-Rad, Hercules, California,
USA) containing 5% β-mercaptoethanol, which was
boiled for 10 min at 56 °C, separated by 4–20% sodium
dodecyl sulfate polyacrylamide gel electrophoresis, and
electrophoretically transferred onto nitrocellulose mem-
branes (Bio-Rad). Membranes were then blocked with
4% bovine serum albumin for 1 h at room temperature,
washed with Tris-buffered saline-Tween 20, and incubated
with mouse monoclonal (IMG17B5F11) anti-CD39 (1/
1000; Abcam, cat:178572), or mouse monoclonal anti β-
actin (1/4000; Abcam, cat: 8226) antibodies for 1 h at
room temperature. Membranes were then washed, incu-
bated with horseradish peroxidase-conjugated anti-mouse
secondary antibodies (Dako, Carpinteria, CA, USA) for
1 h at room temperature, and developed using Enhanced
ECL (Bio-Rad). β-actin was used for normalization of total
protein in each lane.
Densitometry was performed and represented as a
ratio of the pixel intensity of the CD39 illuminated pro-
tein compared with β-actin protein, using a multi-gage.
Normalized values are expressed as the fold change form
values obtained in control samples.
In situ ATPase activity
Localization of ATPase activity was determined using the
Wachstein/Meisel lead phosphate method [21]. Briefly,
OCT tissue sections were rinsed in PBS and then pre-
incubated for 1 h at room temperature in 50 mM Tris-
maleate buffer, at pH 7.4, which contained 2 mM CaCl2
and 0.25 M sucrose. Enzymatic reaction was performed
for 1 h at 37 °C in the same buffer, supplemented with
5 mM MnCl2, 2 mM Pb(NO3)2, 3% dextran T250, and
2.5 mM levamisole, to inhibit alkaline phosphatase activ-
ity and in the presence of 1 mM ATP as the substrate. For
CD39 inhibition, 1 mM of NF279 (Tocris Bioscience,
Bristol, UK) was added to both the pre-incubation and en-
zymatic reaction buffers. Substrate was omitted in control
experiments and the reaction was revealed by incubation
with 1% (NH4)2S v/v for exactly 1 min. Nuclei were
counterstained with haematoxylin, before samples were
dehydrated, mounted with DPX mounting medium, and
observed and photographed under light microscopy.
ATPase activity assays in tissue homogenates
Frozen samples of lung tissue were homogenized in a
phosphate-free buffer containing 20 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) at pH 7.4
with 250 mM sucrose, 1 mM EGTA, 1 mM MgCl, 0.3 mM
PMSF, and 1 mM DTT. ATPase activity was determined
using a malachite green phosphate assay kit (BioAssay
Systems, Hayward, California, CA, USA). Lung tissue
homogenates (5 μg) were added to an incubation mixture
containing 160 mM Tris-HCl (pH 7.5), 10 mM CaCl2, and
5 mM levamisole, as alkaline phosphatase inhibitor. The
reaction started by adding 1 mM ATP as substrate for 1 h
at 37 °C. Controls to determine non-enzymatic inorganic
phospathe (Pi) accumulation were performed by incubating
the samples either with or without the substrate. All
samples were analyzed in triplicate, and the specific activity
is expressed as arbitrary units (AU).
Further details on methods are reported in the Additional
file 1, available at Respiratory Research online.
Statistical analysis
Continuous variables were compared by Student’s t-test
and are expressed as mean ± standard deviation (SD) or
by Mann–Whitney U-test and expressed as median and
interquartile range, regardless of whether a normal distri-
bution was assumed or not, respectively, based on the
Kolmogorov–Smirnov test. Qualitative variables were
compared with the chi-square. Comparisons between
groups were evaluated by one-way analysis of variance
(ANOVA) or Kruskal-Wallis test, as appropriate, and an
overall p-value was calculated. Adjusted analyses were
performed using unbalanced demographic variables as co-
variate (gender, tobacco exposure and the presence of dia-
betes mellitus, p < 0.05). Spearman’s correlation was also
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used to assess the relationship between biological variables
(the percentage of intimal area in pulmonary arteries and
the CD39-related gene expression). Statistical analysis was
performed using IBM SPSS, version 19.0 (IBM Corp.,
Armonk, NY, USA). A p-value < 0.05 was considered statis-
tically significant.
Study endpoints and power calculation
The primary study endpoint was the difference in CD39
gene expression in the COPD group compared to the NS
group. Assuming a standard deviation of 0.77 × 10− 3 in the
CD39 mRNA (ddDt) of the control group, a sample size of
13 subjects per group was needed to detect a minimal
difference of 0.70 × 10− 3 between groups with an 80%
power and a two-tailed p-value less than 0.05. Allowing for
an approximate 15% dropout rate (e.g. inadequate samples
for measurements), including 15 subjects per group was
expected to be sufficient to provide data from 13 samples
for each analysis. Secondary endpoints included between-
group comparisons of CD39 protein expression and immu-
noreactivity in the lungs.
Results
Lung samples from 56 patients undergoing lung resection
were included, of which 10 samples were discarded due to
poor quality or insufficient samples. Therefore, 46 patients
were included (17, 16, and 13 in the COPD, NOS, and NS
groups, respectively). There were no significant differences
in baseline characteristics between groups, except for
gender, tobacco exposure, and the presence of diabetes
(Table 1), so these were included as covariates in all
adjusted analyses.
Gene expression in lung tissue samples
The qRT-PCR analyses showed that CD39 was signifi-
cantly downregulated in the COPD group compared with
both the NOS and NS groups (1.17 [0.85–1.81] vs 1.88
[1.35–4.41] and 3.32 [1.23–5.39], respectively, p = 0.037)
(Fig. 1). In addition, there was a statistically significant
inverse correlation between CD39 gene expression in lung
tissue and serum C-reactive protein levels (Spearman’s
rho = − 0.462, p = 0.005).
Morphometric measurements of intimal thickening
The results of morphometric measurements performed in
pulmonary muscular arteries are shown in Table 2. As
shown, the intimal layer was enlarged in the COPD group
compared with the NOS and NS groups, in agreement with
previous studies [19, 20]. However, the thickness of the
muscular layer in these arteries did not show any significant
between-group differences. There was a significant correl-
ation between the intimal thickening of pulmonary muscu-
lar arteries (expressed as percentage of total area) and lung
CD39 gene expression (Spearman’s rho = 0.39, p = 0.032).
Immunolabeling
As expected, CD39 was expressed in lung parenchyma,
bronchial epithelia, and the endothelial cells of muscular
Table 1 Baseline characteristics and pulmonary function parameters by study group
Characteristic COPD (N = 17) NOS (N = 16) NS (N = 13) p-value
Male gender, n (%) 15 (88) 16 (100) 5 (38) < 0.001
Age, years 64.4 ± 7 61.0 ± 11 61 ± 14 0.617
BMI, kg/m2 25.4 ± 4.2 27.4 ± 4.5 27.2 ± 4.2 0.364
Current smokers, n (%) 3 (17) 9 (56) – < 0.001
Pack-years 51.47 ± 15.52 39.87 ± 19.09 – 0.072
Diabetes Mellitus, n (%) 1 (6) 6 (37.5) – 0.005
Fast basal glucose, mmol/L 5.2 [4.7–6.6] 6.5 [5.2–7.3] 5.3 [4.9–6.3] 0.056
Systemic hypertension, n (%) 8 (34.8) 7 (43.7) 5 (31.3) 0.896
Inhaled CS, n (%) 5 (29.0) 0 (0) 1 (7) 0.039
FVC, L 3.3 ± 0.7 4 ± 0.9 3.5 ± 1 0.079
FVC, % predicted 89 ± 14 101 ± 17 111 ± 23 0.008
FEV1, L 1.9 ± 0.5 3 ± 0.6 2.7 ± 0.8 < 0.001
FEV1, % predicted 64 ± 16 97 ± 14 106 ± 23 < 0.001
% FEV1/FVC 57 ± 10 76 ± 5 77 ± 5 < 0.001
DLCO,% predicted 69 ± 14 89 ± 17 93 ± 18 < 0.001
Leukocytes count, x10E9/L 8.7 ± 1.9 8.2 ± 2 6.9 ± 1.5 0.038
C-reactive protein, mg/L 5.4 [2.1–10.6] 2.1 [1.0–10.9] 1.8 [1–2.7] 0.028
Data are presented as mean ± SD or median [25th–75th percentile]
COPDChronic Obstructive Pulmonary Disease, NOS Non-obstructed smokers, NS Never smokers, BMI Body mass index, CS Corticosteroids, FVC Forced vital capacity,
FEV1 Forced expiratory volume in one second, DLCO Diffusing lung capacity for carbon monoxide. A p-value < 0.05 was considered statistically significant
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pulmonary arteries. In all these structures, CD39 immuno-
labeling was weaker in the COPD group than in the NOS
and NS groups (Table 3). Representative images showing
the downregulation of CD39 in the COPD group com-
pared with the NOS and NS groups are shown in Fig. 2.
Protein expression analysis by western blot
Total CD39 lung content was measured by Western blot.
Densitometric analyses of the bands showed that CD39
band density was lower in the COPD group (0.34 [0.22–
0.92]) compared with the NOS group (0.67 [0.32–1.06])
and the NS group (0.95 [0.4–1.1]) (Fig. 3; p = 0.133). How-
ever, the differences were not statistically significant.
In situ enzyme histochemistry and ATPase activity in lung
tissue homogenates
To determine if the differences in CD39 gene and protein
expression produced changes in enzyme activity between
groups, we assessed ATPase activity. Our results con-
firmed that ATPase activity was present in the lung paren-
chyma, bronchi, and pulmonary arteries (Fig. 4a). The
specific ATPase inhibitor, NF279, also effectively abolished
those activities. Finally, quantification of ATPase activity
in lung homogenates demonstrated that patients with
COPD had decreased ATP hydrolysis (Fig. 4b; p < 0.01)).
Discussion
Increased extracellular levels of ATP in the pulmonary
samples of patients with COPD have been linked to
inflammation and emphysema [22, 23]. Few studies have
addressed the expression or activity of pulmonary
NTPDases as CD39 in COPD. The focus of our study was
to determine the expression and activity of CD39, the
most efficient NTPDase for degrading ATP, for the first
time in human lung tissue between COPD, NOS, and NS
groups. Although the patients studied have established
COPD, the stage of their disease is not advanced but
mild-moderate, and at this time molecular changes may
be more representative of the initial pathogenic injuries.
Our main result was that CD39 gene expression de-
creased in the COPD group. Data regarding CD39 protein
levels also reflect this trend, but it is not statistically
significant. Consistent with our observations, Kratzer et al.
[24] reported a significant downregulation of CD39
expression in the lung tissue of rats exposed to cigarette
smoke. By contrast, Lazar et al. [17] observed increased
CD39 expression in the leukocytes of a COPD group
compared with smoker and NS groups. These seemingly
contradictory findings might be explained by the differ-
ence in the compartmentalization of CD39 expression in
COPD (lung tissue versus inflammatory cells) [17]. The
increased CD39 expression in leukocytes could compen-
sate for the attenuated CD39 lung expression and combat
airway inflammation in COPD. Tan D et al., [18] demon-
strated enhanced expression of CD39 on circulating T-cell
subsets in patients with an exacerbation of COPD com-
pared with patients with stable COPD. Our results are not
at odds with those of these two previous studies; in fact
they complement our current knowledge of CD39 in
Fig. 1 NTPDase1/CD39 Gene Expression in Human Lung Tissue
Samples. Relative mRNA levels of CD39 analyzed in the COPD (n = 15),
NOS (n = 13) and NS (n = 11) groups, normalized to 18 S mRNA levels
and expressed as fold changes. Data are expressed as median ± rank.
*Significantly different from NS and NOS (P < 0.05). Abbreviations:
NTPDase1, nucleoside triphosphate diphosphohydrolase-1; COPD,
Chronic obstructive pulmonary disease; NOS, Non-obstructed smokers;
NS, Never smoker
Table 2 Morphometric characteristics in pulmonary muscular arteries by study group
COPD (N = 12) NOS (N = 8) NS (N = 12) p-value
N° of arteries measured by patient 10 ± 4 12 ± 6 8 ± 6 0.203
Artery diameter, μm 306 ± 65 349.33 ± 57.7 333.51 ± 18.8 0.186
Lumen area, % total area 27.7 ± 7.1 35.1 ± 8.2 36.2 ± 9.8 0.046
Intimal area, % total area 37.3 ± 7 29.4 ± 7.1 26.6 ± 11.5 0.018
Muscular area, % total area 35 ± 4.2 35.5 ± 5.9 37.2 ± 11.2 0.782
Index of narrowinga 0.299 ± 0.032 0.301 ± 0.024 0.307 ± 0.269 0.831
COPD Chronic Obstructive Pulmonary Disease, NOS Non-obstructed smokers, NS Never smokers
Data are presented as median ± standard deviation. P-values are for the overall comparison by ANOVA
aIndex of narrowing was estimated as the ration between the measured total area and the area extrapolated from the theoretical distended diameter: (theoretical
diameter = length of the external elastic lamina/pi (π))
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Table 3 Analysis of CD39 immunostaining intensity by study group
CD39 Stain Score for lung parenchyma COPD NOS NS
+++ 1 (6,66) 0 (0) 1 (8,33)
++ 3 (20) 8 (61,53) 6 (50)
+ 10 (66,66) 4 (30,78) 4 (33,33)
0 1 (6,66) 1 (7,69) 1 (8,33)
Total of Samples 15 13 12
CD39 Stain Score for the Bronchi COPD NOS NS
+++ 5 (12,82) 16 (25,4) 25 (40,32)
++ 9 (23,08) 30 (47,62) 29 (46,77)
+ 21 (53,84) 17 (26,98) 8 (12,9)
0 4 (10,25) 0 (0) 0 (0)
Total of Bronchus 39 63 62
Total of Samples 12 12 12
CD39 Stain Score for the Muscular Pulmonary Artery COPD NOS NS
+++ 20 (9,13) 7 (4,46) 19 (17,59)
++ 38 (17,35) 52 (33,12) 39 (36,11)
+ 80 (36,53) 58 (36,94) 43 (39,81)
0 81 (36,98) 40 (25,48) 7 (6,48)
Total of Pulmonary Artery 219 157 108
Total of Samples 15 13 12
COPD Chronic Obstructive Pulmonary Disease, NOS Non-obstructed smokers, NS Never smokers. Number of samples, Stain Intensity and Percentage are shown for each result
Fig. 2 Immunolocalization of NTPDase1/CD39 in Human Lung Structures: Parenchyma (a–d), Bronchi (e–h), and Pulmonary Arteries (i–l). CD39
was downregulated in lung parenchyma, bronchial epithelial cells, and endothelial cells of pulmonary arteries in the COPD group. Images are of
representative histological slides from the COPD (n = 15), NOS (n = 13), and NS (n = 12) groups. The primary antibody was omitted in the control
experiments in images D, H, and L. Scale bars = 100 μm. Abbreviations: NTPDase1, nucleoside triphosphate diphosphohydrolase-1; COPD, Chronic
obstructive pulmonary disease; NOS, Non-obstructed smokers; NS, Never smoker
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COPD. We show that the expression of CD39 in lung
tissue in patients with COPD (in the initial phase) is
diminished; therefore, as found in the animal model of
Lazar et al. [17], administering a CD39 analogue might
protect against the development of pulmonary emphy-
sema and inflammation in human patients as well. Our
study did not analyze the expression of CD39 in the
pulmonary or systemic inflammatory cells. However, the
increase in CD39 expression in airway and systemic
inflammatory cells suggested by both articles may be the
compensatory mechanism for acute exposure to tobacco
[17] or infection [18].
Attenuation of lung CD39 expression in COPD could
be responsible for the increased ATP levels detected in
pulmonary samples from patients with COPD [23].
Interestingly, it has been reported that the high amounts
of ATP detected during asthma exacerbations could be
due to reduced leukocyte expression of ectonucleotide
pyrophosphatase/ phosphodiesterase 1 (ENPP1), another
ATP degrading enzyme [25]. Furthermore, CD39 has
been shown to be involved in the pathogenesis of allergic
inflammation by modulating dendritic cell function [26].
Fig. 3 Lung NTPDase1/CD39 Protein Expression Divided by Groups.
Analyses of total lung tissue showing the band densities of CD39
in the COPD (n = 13), NOS (n = 12), and NS (n = 12) groups. CD39
protein levels were lower in the COPD group. Data are expressed
as median ± rank. Abbreviations: NTPDase1, nucleoside triphosphate
diphosphohydrolase-1; COPD, Chronic obstructive pulmonary disease;
NOS, Non-obstructed smokers; NS, Never smoker
Fig. 4 In Situ Enzyme Histochemistry and ATPase Activity in Lung Tissue Homogenates. a Examples of enzyme in situ histochemistry in lung
structures such as parenchyma, bronchus and pulmonary artery from NOS. The localization of ATPase activity is showed as dark brown deposits.
Scale bar = 100 μm. b ATPase enzyme activity in tissue homogenates for the COPD, NOS, and NS groups (n = 7, per group). Experiments were
performed in triplicate for each sample. Data are represented in arbitrary units (AU). * Significant differences at p < 0.05. Abbreviations: COPD,
Chronic obstructive pulmonary disease; NOS, Non-obstructed smokers; NS, Never smoker
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We compared the localization and expression of CD39 in
the lung samples of COPD, NOS, and NS groups. In the
lung, CD39 is mainly localized in the parenchyma,
bronchial epithelial cells, and endothelial cells. In patients
with cystic fibrosis, CD39 expression has been detected in
alveolar and bronchial epithelial cells and in endothelial
cells [12], and it has also been reported to be expressed in
smooth muscle cells, platelets, and immune cells [27]. Our
results show that lung CD39 expression, was diminished in
all lung structures of patients with COPD. This pulmonary
scenario, with a high ATP niche, favors proinflammatory
responses of the innate immune system via the activation
of ATP receptors (e.g., P2X) expressed in human airways
[28] and on the surface of immune cells [29].
Enzymatic ATPase activity was demonstrated in lung
tissue samples. Previously, pulmonary ATPase activity has
been shown in the bronchoalveolar lavage fluid of humans
and mice exposed to cigarette smoke [17]. As expected,
ATPase activity was found in the same structures where it
was immunolocalized (i.e., the parenchyma, bronchi, and
pulmonary artery). In addition, when we quantified ATPase
activity and compared it between groups, activity was
significantly lower in the COPD group. Decreased CD39
activity has been shown in tissue compartments due to
oxidative stress and proinflammatory cytokines like tumor
necrosis factor-α [30]. Recently, it has been suggested that
pharmacological therapies aimed at neutralizing ATP or
blocking its receptors could be used to treat COPD. To
date, the efficacy of this therapy has only been demon-
strated in mice [7].
We also showed that downregulation of CD39 gene
expression correlated with increased blood C-reactive pro-
tein levels. Systemic inflammation, which has previously
been described in a high proportion of patients with stable
COPD, has also been associated with a worse prognosis
and higher mortality [31]. In the present research, we
showed an inverse association between both biomarkers.
This finding provides further support for the compensa-
tory theory of the increase in CD39 in circulating blood
inflammatory cells associated with the exacerbation of
COPD described in a previous article [18].
We also observed that lung samples with fewer CD39
gene expressions have greater vascular intimal thicken-
ing. We hypothesized that downregulation of pulmonary
CD39 led to ATP accumulation and thereby created a
beneficial environment for inflammation and remodel-
ing. Recently, attenuated CD39 enzyme activity in
endothelial cells has been associated with vascular
remodeling in patients with idiopathic pulmonary arter-
ial hypertension [32]. To further investigate the contri-
bution of decreased CD39 levels to the pathobiology of
pulmonary hypertension in COPD, it would be interest-
ing to study CD39 expression in muscular pulmonary
arteries and its relationship to vascular remodeling in
patients with pulmonary hypertension secondary to
COPD.
Several limitations of this study need to be discussed.
First, there were few females in both the COPD and NOS
groups (most patients with major smoking habits were
male). This makes it difficult to draw conclusions about
the role of sex. Second, the study population included
those with primary, localized, and treatable lung cancer;
therefore, lung cancer could be a possible introduced bias.
However, we assumed that any bias introduced by the
presence of lung carcinoma would be the same across all
subjects, and this must be considered when comparing
CD39 expression and differences between the COPD,
NOS, and NS groups. On the other hand, this is the only
model that allows us to correlate clinical and analytical
data and data on lung function, in stable patients and in
those at the initial stages of the disease, with the structural
and biological characteristics of the lung tissue from the
same patients.
Finally, due to the study’s observational design, no causal
conclusions can be drawn, and we may only state that there
was an association between the presence of COPD and the
low expression of CD39.
Conclusions
Our data show an attenuation of CD39 expression and
activity in lung tissue of stable mild COPD patients. These
results could explain the pulmonary accumulation of
extracellular ATP in the lung, previously demonstrated in
COPD patients, which confers increased proinflammatory
responses favouring the development of emphysema.
Further studies are needed to better understand the real
role of CD39 in this COPD context.
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